Table 1 Comparison of the characteristics of study participants on training, retrospective test and prospective test dataset
|  | Train set (2019–2020) | Retrospective test set (2019–2020) | p value between training and retrospective test set | Prospective test set (2021) | p value between training and prospective test set |
|---|---|---|---|---|---|
Number of visits | 53,410 | 13,353 | Â | 14,742 | Â |
Venous thromboembolism | 339 (0.63%) | 85 (0.64%) | 0.981 | 135 (0.92%) | < 0.001 |
Age: 18–40 years | 14,332 (26.83%) | 3571 (26.74%) | 0.832 | 3571 (24.22%) | < 0.001 |
Age: 41–60 years | 23,836 (44.63%) | 5924 (44.36%) | 0.584 | 6902 (46.82%) | < 0.001 |
Age: 61–75 years | 12,301 (23.03%) | 3098 (23.2%) | 0.677 | 3379 (22.92%) | 0.778 |
Age: 75 + years | 2941 (5.51%) | 760 (5.69%) | 0.403 | 890 (6.04%) | 0.013 |
Gender: male | 23,412 (43.83%) | 5890 (44.11%) | 0.566 | 6622 (44.92%) | 0.018 |
Gender: female | 29,998 (56.17%) | 7463 (55.89%) | 0.567 | 8120 (55.08%) | 0.020 |
BMI > 25 kg/m2 | 17,878 (33.47%) | 4482 (33.57%) | 0.840 | 5233 (35.5%) | < 0.001 |
Bedridden status | 3454 (6.47%) | 891 (6.67%) | 0.388 | 1390 (9.43%) | < 0.001 |
History of DVT or PE | 86 (0.16%) | 33 (0.25%) | 0.036 | 40 (0.27%) | 0.006 |
Malignancy | 15,846 (29.67%) | 3867 (28.96%) | 0.109 | 4768 (32.34%) | < 0.001 |
Abnormal platelet counts | 1276 (2.39%) | 311 (2.33%) | 0.684 | 337 (2.29%) | 0.466 |
Abnormal carcinoembryonic antigen levels | 1065 (1.99%) | 257 (1.92%) | 0.607 | 266 (1.8%) | 0.141 |
Abnormal triglyceride levels | 1745 (3.27%) | 434 (3.25%) | 0.921 | 617 (4.19%) | < 0.001 |
Abnormal hemoglobin levels | 1832 (3.43%) | 460 (3.44%) | 0.933 | 530 (3.6%) | 0.332 |
Major surgery | 39,463 (73.89%) | 9865 (73.88%) | 0.984 | 11,412 (77.41%) | < 0.001 |